Trial reportMalaria journal2012
Prospective evaluation of artemether-lumefantrine for the treatment of non-falciparum and mixed-species malaria in Gabon.
Trial report in Malaria journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00725777 (Efficacy and Safety of Artemether Lumefantrine Combination Therapy for the Treatment of Malaria Due to Plasmodium Ovale, Plasmodium Malariae, and Mixed Plasmodium Infections in Gabon), which is not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Artemether Lumefantrine Combination Therapy for the Treatment of Malaria Due to Plasmodium Ovale, Plasmodium Malariae, and Mixed Plasmodium Infections in Gabon
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review.Malaria journal · 2014Pooled it
- Effectiveness of pyronaridine-artesunate against Plasmodium malariae, Plasmodium ovale spp, and mixed-Plasmodium infections: a post-hoc analysis of the CANTAM-Pyramax trial.The Lancet. Microbe · 2022Trial
- Trial
- Ex Vivo Drug Susceptibility ofPathogens (Basel, Switzerland) · 2025Article
- Congenital infection with Plasmodium malariae: a rare case of intrauterine transmission in Germany.Malaria journal · 2025Article
- A cross-sectional analysis identifies a low prevalence ofWellcome open research · 2022Article
- Artemether/Lumefantrine for the Treatment ofCase reports in medicine · 2019Article
- In Vivo Anti-Malarial Activity ofIranian journal of public health · 2018Article
- Prospective Clinical Trial Assessing Species-Specific Efficacy of Artemether-Lumefantrine for the Treatment of Plasmodium malariae, Plasmodium ovale, and Mixed Plasmodium Malaria in Gabon.Antimicrobial agents and chemotherapy · 2018Article
- Species and genotype diversity of Plasmodium in malaria patients from Gabon analysed by next generation sequencing.Malaria journal · 2017Article
- Genomic Characterization of Recrudescent Plasmodium malariae after Treatment with Artemether/Lumefantrine.Emerging infectious diseases · 2017Article
- Non-falciparum malaria in Dakar: a confirmed case of Plasmodium ovale wallikeri infection.Malaria journal · 2016Article
- Plasmodium malariae Infection Associated with a High Burden of Anemia: A Hospital-Based Surveillance Study.PLoS neglected tropical diseases · 2015Article
- Delayed Onset of Symptoms and Atovaquone-Proguanil Chemoprophylaxis Breakthrough by Plasmodium malariae in the Absence of Mutation at Codon 268 of pmcytb.PLoS neglected tropical diseases · 2015Article
- Detection of persistent Plasmodium spp. infections in Ugandan children after artemether-lumefantrine treatment.Parasitology · 2014Article
- Persistent detection of Plasmodium falciparum, P. malariae, P. ovale curtisi and P. ovale wallikeri after ACT treatment of asymptomatic Ghanaian school-children.International journal for parasitology. Drugs and drug resistance · 2013Article
- Acute respiratory distress syndrome and acute renal failure from Plasmodium ovale infection with fatal outcome.Malaria journal · 2013Article
- Management of imported malaria in Europe.Malaria journal · 2012Review
- Advances in the treatment of malaria.Mediterranean journal of hematology and infectious diseases · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe recommendation of artemisinin combination therapy (ACT) as first-line treatment for uncomplicated falciparum malaria is supported by a plethora of high quality clinical trials. However, their recommendation for the treatment of mixed-species malaria and the large-scale use for the treatment of non-falciparum malaria in endemic regions is based on anecdotal rather than systematic clinical evidence.
methodsThis study prospectively observed the efficacy of artemether-lumefantrine for the treatment of uncomplicated non-falciparum or mixed-species malaria in two routine district hospitals in the Central African country of Gabon.
resultsForty patients suffering from uncomplicated Plasmodium malariae, Plasmodium ovale or mixed-species malaria (including Plasmodium falciparum) presenting at the hospital received artemether-lumefantrine treatment and were followed up. All evaluable patients (n=38) showed an adequate clinical and parasitological response on Day 28 after oral treatment with artemether-lumefantrine (95% confidence interval: 0.91,1). All adverse events were of mild to moderate intensity and completely resolved by the end of study.
conclusionsThis first systematic assessment of artemether-lumefantrine treatment for P. malariae, P. ovale and mixed-species malaria demonstrated a high cure rate of 100% and a favourable tolerability profile, and thus lends support to the practice of treating non-falciparum or mixed-species malaria, or all cases of malaria without definite species differentiation, with artemether-lumefantrine in Gabon.
trial registrationClinicalTrials.gov Identifier: NCT00725777.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.